BioMarin Pharmaceutical

BioMarin Pharmaceutical

BMRN
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

BMRN · Stock Price

USD 54.12-5.70 (-9.53%)
Market Cap: $10.5B

Historical price data

Market Cap: $10.5BPipeline: 121 drugs (30 Phase 3)Patents: 20Founded: 1997Employees: ~3,000HQ: San Rafael/Novato, United States

Overview

BioMarin Pharmaceutical is a mission-driven, revenue-generating biotech leader with a 25+ year track record of translating genetic insights into transformative medicines for rare diseases. The company's strategy centers on pursuing 'category-defining' therapies in areas of well-understood biology, leveraging core platforms in enzyme replacement therapy (ERT) and gene therapy. This approach has yielded a commercial portfolio generating significant revenue and a promising clinical pipeline, underpinned by global commercial and manufacturing infrastructure. BioMarin's financial strength and operational maturity support its ambition to sustainably deliver breakthrough science to patients worldwide.

Rare Genetic DiseasesLysosomal Storage Disorders

Technology Platform

Integrated platforms in Enzyme Replacement Therapy (ERT) for lysosomal storage disorders and advanced Gene Therapy using AAV vectors for monogenic diseases.

Pipeline

121
121 drugs in pipeline30 in Phase 3
DrugIndicationStageWatch
NaglazymeMucopolysaccharidosis VIApproved
saproterin dihydrochloridePhenylketonuriaApproved
Pegvaliase + MethotrexatePhenylketonuriaApproved
Kuvan®PhenylketonuriaApproved
KuvanPhenylketonuria (PKU)Approved

Funding History

2
Total raised:$52M
IPO$42M
Series A$10M

FDA Approved Drugs

7
VOXZOGONDANov 19, 2021
PALYNZIQBLAMay 24, 2018
BRINEURABLAApr 27, 2017

Company Timeline

1997Founded

Founded in San Rafael/Novato, United States

1997Series A

Series A: $10.0M

1999IPO

IPO — $42.0M

2017FDA Approval

FDA Approval: BRINEURA

2018FDA Approval

FDA Approval: PALYNZIQ

2021FDA Approval

FDA Approval: VOXZOGO